AAT 730
Alternative Names: AAT-730; OCT-461201; OCT461201 - Oxford Cannabinoid Technologies; RQ-00202730Latest Information Update: 07 May 2024
At a glance
- Originator Pfizer
- Developer AskAt; Oxford Cannabinoid Technologies
- Class Analgesics; Benzimidazoles; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Irritable bowel syndrome; Neuropathic pain; Visceral pain
- Preclinical Pain; Postherpetic neuralgia
Most Recent Events
- 10 Apr 2023 Phase-I clinical trials in Neuropathic pain (PO) (Oxford Cannabinoid Technologies pipeline, April 2023)
- 10 Apr 2023 Phase-I clinical trials in Visceral pain (PO) (Oxford Cannabinoid Technologies pipeline, April 2023)
- 01 Apr 2023 Phase-I clinical trials in Irritable bowel syndrome (In volunteers) in United Kingdom (PO) before April 2023 (Oxford Cannabinoid Technologies pipeline, April 2023)